1 |
World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection [Internet]. Geneva (Switzerland): World Health Organization; 2018 [cited 2019 Sep 15]. Available from: https://www.who.int/hepatitis/publications/hepatitisc-guidelines-2018.
|
2 |
Kim BK, Jang ES, Kim JH, Park SY, Ahn SV, Kim HJ, et al. Current status of and strategies for hepatitis C control in South Korea. Clin Mol Hepatol 2017;23:212-8.
DOI
|
3 |
Indolfi G, Serranti D, Resti M. Direct-acting antivirals for children and adolescents with chronic hepatitis C. Lancet Child Adolesc Health 2018;2:298-304.
DOI
|
4 |
Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52:501-7.
DOI
|
5 |
Rashed YK, Khalaf FA, Kotb SE. Thyroid disturbances in children treated with combined Pegylated Interferon alpha and Ribavirin for chronic hepatitis C. Clin Exp Pediatr 2020;63:52-5.
DOI
|
6 |
Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006;43:661-72.
DOI
|
7 |
Hwang Y, Kim W, Kwon SY, Yu HM, Kim JH, Choe WH. Incidence of and risk factors for thyroid dysfunction during peginterferon and ribavirin treatment in patients with chronic hepatitis C. Korean J Intern Med 2015;30:792-800.
DOI
|
8 |
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018;69:461-511.
DOI
|
9 |
The American Association for the Study of Liver Diseases, the Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C [Internet]. AASLD, IDSA;[cited 2019 Sep 14]. Available from: https://www.hcvguidelines.org.
|